Evidence map›Paper›PMID 21540763›Full record

ArticlePharmacogenetics and genomics2011

Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck.

Hongping Yu, Li-E Wang, Zhensheng Liu, Sheng Wei, Guojun Li, Erich M Sturgis, Qingyi Wei

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenetics and genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Associations ofJournal of clinical medicine · 2021
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Oncotarget · 2017
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hongping YuDepartments of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Li-E Wang
Zhensheng Liu
Sheng Wei
Guojun Li
Erich M Sturgis
Qingyi Wei
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Molecular Epidemiology of Head and Neck CancerR01ES011740 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2001 to 2012
$6.3M
Genotypes and Phenotypes of Apoptosis and Risk of Head and Neck CancerR01CA131274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2009 to 2013
$3.0M
Humanized Mouse Models for the p53 R72P SNPR01ES015587 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JOHNSON, DAVID G. · 2009 to 2013
$2.2M
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA131274NIEHS NIH HHS ES015587NIEHS NIH HHS R01 ES011740NIEHS NIH HHS R01 ES015587
6 · The paper itself

Abstract

purposeMouse double minute 4 (MDM4), a homolog of MDM2, is one of the key negative regulators of p53, and its amplification or overexpression contributes to carcinogenesis by inhibiting the p53 tumor suppressor activity. We investigated the association between MDM4 polymorphisms and the risk of squamous cell carcinoma of the head and neck (SCCHN).

methodsWe genotyped three MDM4 tagging polymorphisms, two in the 3' untranslated region (rs11801299G>A and rs10900598G>T) and one in intron 1 (rs1380576C>G), in a case-control study of 1075 non-Hispanic white SCCHN patients and 1079 cancer-free controls, and evaluated their associations with SCCHN risk.

resultsAlthough none of these three polymorphisms individually had a statistically significant effect on the risk of SCCHN, nor did their combined number of putative risk genotypes (i.e. rs11801299GG, rs1380576CG+GG, and rs10900598GG) [odds ratio (OR)=1.16; 95% confidence interval (95% CI) =0.93-1.45], we found that individuals with 1-3 risk genotypes had statistically significant increased risk of oropharyngeal cancer (OR=1.32; 95% CI=1.00-1.73), particularly for those with T1-2 stage (OR=1.40; 95% CI=1.02-1.94), those with regional lymph node metastases (N1-3) (OR=1.44; 95% CI=1.07-1.95), and those with late stages (III and IV) (OR=1.34; 95% CI=1.01-1.77).

conclusionThese results suggest that the joint effect of MDM4 variants may contribute to the risk of oropharyngeal cancer in non-Hispanic whites. Additional studies are warranted to unravel whether the particular stage distribution of oropharyngeal cancer with the strongest association (T1-2, N1-3, and III-IV) is a possible link with human papillomavirus-related oropharyngeal cancers.

Indexed as

AgedCarcinomaCarcinoma, Squamous CellCase-Control StudiesCell Cycle ProteinsFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasms, Squamous CellNeoplasm StagingNuclear ProteinsPolymorphism, GeneticPolymorphism, Single NucleotideProto-Oncogene ProteinsCell Cycle ProteinsMDM4 protein, humanNuclear ProteinsProto-Oncogene Proteins

Identifiers

PMID21540763
PMCPMC3116079
OpenAlexW2021626734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.